Medical Condition

atrial fibrillation

Total Trials

37

Recruiting Now

37

Trial Phases

Phase 4, Phase 2, Phase 3

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting over 33 million people worldwide and conferring a fivefold increased risk of stroke. Clinical trials in AF address three core problems: rhythm control (restoring and maintaining sinus rhythm), rate control (controlling heart rate in persistent AF), and stroke prevention (anticoagulation). The EAST-AFNET 4 trial established early rhythm control as superior to a rate-control strategy in reducing cardiovascular events, reshaping international guidelines.

Current trials evaluate non-vitamin K oral anticoagulants (NOACs) in underserved populations, pulse field ablation versus radiofrequency ablation (ADVENT trial showed non-inferiority), left atrial appendage occlusion devices (WATCHMAN FLX) versus NOAC therapy in patients with bleeding risk, and novel antiarrhythmic drugs with improved safety profiles. Digital health trials using smartwatch-detected AF episodes are emerging as enrollment and monitoring tools.

CHAβ‚‚DSβ‚‚-VASc score determines anticoagulation eligibility; prior ablation history and type of AF (paroxysmal, persistent, long-standing persistent) determine eligibility for rhythm control trials.

Frequently Asked Questions — atrial fibrillation Clinical Trials

How many clinical trials are currently recruiting for atrial fibrillation?

ClinicalMetric currently tracks 37 actively recruiting clinical trials for atrial fibrillation, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 37. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for atrial fibrillation?

atrial fibrillation research spans Phase 2 (2 trials), Phase 3 (1 trial), Phase 4 (6 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a atrial fibrillation clinical trial?

Eligibility criteria for atrial fibrillation trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 2

Phase 3

Phase 4

Top Sponsors

Biosense Webster, Inc. 2 trials

Insel Gruppe AG, University Hospital Bern 2 trials

Vrinnevi Hospital 1 trial

Seoul National University Hospital 1 trial

University of Birmingham 1 trial

atrial fibrillation

Frequently Asked Questions — atrial fibrillation Clinical Trials

Recruiting Clinical Trials

Related Conditions